













- enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. *Circulation*. 2001;104:642-7.
26. Zhang M, He H, Wang ZM, Xu Z, Zhou N, Tao Z, Chen B, Li C, Zhu T, Yang D, Wang L, Yang Z. Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study. *J Biomed Res*. 2014;28:98-107.
27. Kizer JR, Muttref MR, Matthai WH, McConnell J, Nardone H, Sonel AF, Keane MG, Wilensky RL. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. *Eur Heart J*. 2003;24:1314-22.
28. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. *Eur Heart J*. 2006;27:1061-9.
29. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, Rubartelli P, Battaglia S, Niccoli L, Steffenino G, Ardissino D; Italian 'Atherosclerosis, Thrombosis, and Vascular Biology' and 'Society for Invasive Cardiology-GISE' Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. *Eur Heart J*. 2005;26:1494-8.
30. Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome. *Ann Clin Biochem*. 2002;39:392-7.
31. Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le Feuvre C, Collet JP, Montalescot G; ACTION Study Group. Periprocedural myocardial infarction and injury in elective coronary stenting. *Eur Heart J*. 2018;39:1100-9.
32. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283:2008-12.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539-58.
35. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. *Epidemiology*. 1993;4:218-28.
36. Lindsey JB, Kennedy KF, Stolker JM, Gilchrist IC, Mukherjee D, Marso SP, Pencina MJ, Kleiman NS, Cohen DJ. Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. *Circ Cardiovasc Interv*. 2011;4:474-80.
37. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011;124:e574-651.
38. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. *J Am Coll Cardiol*. 2003;42:1406-11.
39. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Cho KI, Kim BH, Je HG, Park YH. Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis. *Catheter Cardiovasc Interv*. 2013;81:959-67.
40. Lo N, Michael TT, Moin D, Patel VG, Alomar M, Papayannis A, Cipher D, Abdullah SM, Banerjee S, Brilakis ES. Periprocedural myocardial injury in chronic total occlusion percutaneous interventions: a systematic cardiac biomarker evaluation study. *JACC Cardiovasc Interv*. 2014;7:47-54.
41. Chen ZW, Yang HB, Chen YH, Ma JY, Qian JY, Ge JB. Impact of multi-vessel therapy to the risk of periprocedural myocardial injury after elective coronary intervention: exploratory study. *BMC Cardiovasc Disord*. 2017;17:69.
42. Jeremias A, Kleiman NS, Nassif D, Hsieh WH, Pencina M, Maresh K, Parikh M, Cutlip DE, Waksman R, Goldberg S, Berger PB, Cohen DJ; Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry Investigators. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. *Circulation*. 2008;118:632-8.
43. Ndrepepa G, Colleran R, Braun S, Cassese S, Hieber J, Fusaro M, Kufner S, Ott I, Byrne RA, Husser O, Hengstenberg C, Laugwitz KL, Schunkert H, Kastrati A. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2016;68:2259-68.
44. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. *J Am Coll Cardiol*. 2006;48:1765-70.

## Supplementary data

**Supplementary Figure 1.** Elevated versus non-elevated cardiac troponin I levels and risk of MACE.

**Supplementary Figure 2.** Elevated versus non-elevated cardiac troponin T levels and risk of MACE.

**Supplementary Figure 3.** Elevated versus non-elevated CK-MB levels and risk of MACE.

**Supplementary Figure 4.** Subgroup analysis of the four studies which reported the actual 99% URL of cardiac troponin I.

**Supplementary Table 1.** Characteristics of included studies (cardiac troponin I).

**Supplementary Table 2.** Univariate meta-regression of baseline characteristics for cardiac troponin I and risk of all-cause mortality.

**Supplementary Table 3.** Univariate meta-regression of baseline characteristics for CK-MB and risk of all-cause mortality.

The supplementary data are published online at:

<https://eurointervention.pconline.com/>

doi/10.4244/EIJ-D-19-00737

